Twice-Yearly Blood Pressure Injection Zilebesiran Shows Greater Results Than Daily Pills

A twice-yearly injection called zilebesiran has shown greater blood pressure reductions than standard daily medication in a clinical trial, raising the possibility of a new approach to treating hypertension.

The results, published in April 2026, found that patients who received zilebesiran twice a year had lower blood pressure readings than those taking standard daily pills. Researchers said the drug could be particularly useful for patients who struggle to take medication consistently.

High blood pressure affects nearly half of American adults and is a leading risk factor for heart attack, stroke, and kidney disease. Despite the availability of effective medications, many patients do not achieve adequate control, often because of missed doses.

A twice-yearly injection would remove the daily adherence challenge. Researchers said the drug works by targeting a protein in the liver that plays a key role in regulating blood pressure.

Separate research published this month found that an overlooked hormone, elevated cortisol, may explain why more than a quarter of people with hard-to-treat high blood pressure do not respond to standard treatment. Doctors are being encouraged to test for cortisol excess in patients whose blood pressure remains uncontrolled.

Mind-body practices like Qigong and yoga were also highlighted in April research as potentially useful tools for managing hypertension, particularly for patients who prefer non-pharmacological approaches.

Zilebesiran is still in clinical trials. Regulatory approval would be required before it becomes widely available.